Charles Stahlmann, DO
Pulmonary Disease · Reno, NVNPI 1558667071
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $220,915 of the $263,339 with a category attached, or 83.9%. AstraZeneca accounts for 98.1% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $125,810, more than ten times the $50 reported in 2019. Among pulmonary disease clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 379 payments — averaging $694.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$258K
- Intuitive Surgical$4K
- Inari Medical, Inc.$335
- GSK$322
- Abiomed$127
- Baxter Healthcare$124
- plus $305 from 7 others
What the payments were for
- Speaking & faculty fees$220,91584%
- Travel & lodging$30,69712%
- Food & beverage$8,7093%
- Education$3,0171%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 343 | $258,347 |
| Intuitive Surgical | 8 | $3,779 |
| Inari Medical, Inc. | 2 | $335 |
| GSK | 13 | $322 |
| Abiomed | 1 | $127 |
| Baxter Healthcare | 1 | $124 |
| United Therapeutics Corporation | 1 | $119 |
| Mylan Specialty L.p. | 4 | $58 |
| Vertex | 1 | $48 |
| Boehringer Ingelheim | 2 | $28 |
| La Jolla Pharmaceutical Company | 1 | $22 |
| Insmed, Inc. | 1 | $17 |
| Advanced Respiratory, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$160,548
- FASENRA$61,932
- TEZSPIRE$21,306
- AIRSUPRA$10,455
- ION$3,000
- Da Vinci Surgical System$638
- FLOWTRIEVER CATHETER, S$335
- CT THROMBECTOMY SYSTEM KIT$335
- Impella$127
- Hillrom - Vest System Model 105 Home Care$124
- TYVASO$119
How this compares
$263,339 in reported general payments places this provider in the 95th percentile of 84 pulmonary disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 11 | $77,385 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $54,731 |
| Spiriva RespimatTiotropium Bromide | 14 | $11,004 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $8,810 |
| Wixela InhubFluticasone Propion/Salmeterol | 15 | $2,352 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $955 |
| Montelukast Sodium | 15 | $216 |
| Pantoprazole Sodium | 14 | $172 |
| Furosemide | 12 | $90 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $322 | $54,73151 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $28 | $19,81429 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 84 pulmonary disease providers in Nevada.
Other pulmonary disease in Reno
- William GrahamReno$21K
- Amanda MorganReno$20K
- Steve MashourReno$12K
- Julia ChristopherReno$8K
- Christina SzotReno$7K
- Aleem SuraniReno$2K
- Hafiz MahboobReno$2K
- Kunwardeep DhillonReno$2K
- Aaron VirayReno$2K
- Shibu SkariaReno$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.